Study of avatrombopag and retinoic acid for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a combination of two drugs—avatrombopag and all-trans retinoic acid—in adults with persistent or chronic immune thrombocytopenia (ITP) whose platelet levels stay low despite prior treatments. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had ITP for at least 3 months (persistent or chronic ITP).
- Your platelet count is below 30,000 per microliter, measured at least twice over the past week.
- You have already tried first-line treatments (like steroids or immunoglobulin) and they did not work or you relapsed after them.
- You are not currently taking certain blood thinners or platelet-affecting drugs (unless stable on specific ones).
- You have no history of blood clots, heart disease, or active infections like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
This trial tests adding a new drug (ripertamab) to a standard ITP treatment (eltrombopag) for patients whose platelet count hasn't improved with steroids. The goal is to see if the combination works better at raising platelet counts and lowering bleeding risk.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial compares two treatments for adults recently diagnosed with immune thrombocytopenia (ITP) whose platelet count is very low and hasn't improved with standard steroids. The goal is to find a better way to raise platelet counts and reduce bleeding risk.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.